Cello Health is a new pharmaceutical services platform company backed by Arsenal Capital Partners, a leading private equity firm that specializes in building strategically important, market-leading companies in Healthcare and Specialty Industrials sectors. Our mission is to build a market-leading company focused on improving patient health by accelerating and optimizing access to medical advances. We are building a global organization underpinned by world-class science and leveraging real world data that seeks to support biopharmaceutical companies with the strategy, evidence and tools required to maximize the commercial potential of their products. A large component of our execution strategy is to acquire market-leading companies to build our capability set and enhance our world-class team to succeed in our mission. Our initial acquisition was BresMed Health Solutions in February 2020, a leading provider of health economics and outcomes research supporting the evolution of reimbursement models for costly specialty therapies to better align with clinical and economic effectiveness. In August 2020, we acquired Cello Health Ltd, a leading provider of evidence analysis, strategic consulting, and scientific communications to the biopharmaceutical industry to optimize the path to market for innovative therapies. Cello’s consulting, research, and medical communications capabilities are engaged with the brand, market access, and medical affairs teams of over 400 biopharmaceutical companies globally. We seek to continue our aggressive acquisition strategy, and we are looking to expand our internal Corporate Development team to support our Mamp;A activities.
ARSENAL CAPITAL PARTNERS
Established in 2000, Arsenal Capital Partners is a leading private equity firm that specializes in building strategically important, market-leading companies in Healthcare and Specialty Industrials sectors. Since inception, Arsenal has raised institutional equity investment funds of approximately $5 billion and is currently investing out of its $2.4 billion fifth fund which was raised in 2019. Arsenal’s initial entry point is typically in businesses that have an enterprise value in the range of $100-$500 million. Arsenal’s Healthcare team has built a successful franchise focused on building clear market leading, rapidly growing businesses that make a positive impact on the healthcare system. Arsenal’s portfolio companies make a profound difference in accelerating the process of bringing new therapies to patients, in ensuring high quality, efficient operations of care providers and payers, and in addressing gaps in high quality clinical care delivery. Through their influential network of healthcare companies, Arsenal has established a ubiquitous presence across the healthcare services landscape, serving over 3,500 hospitals, payers covering 80%+ of U.S. covered lives, and nearly all global pharmaceutical and biotech organizations. Since the group came together in 2011, the team has invested in nine platforms, deploying over $2 billion of Arsenal’s and co-investors’ equity capital and building transformational market leaders through organic initiatives and over forty add-on acquisitions.
POSITION DESCRIPTION
Cello Health is looking for a Corporate Development Associate to be an integral member of a tightly-knit and growing team. The Corporate Development Associate is expected to play a central role in supporting all aspects of the organization’s Mamp;A strategy and execution,from identifying target companies and managing the Mamp;A pipeline, to evaluating and executing acquisitions. The Associate will also support internal strategy projects to continually assess our acquisition strategy. The Corporate Development Associate will report to the Senior Vice President and Global Head of Mamp;A and will work closely with the Value Demonstration executive team and Arsenal Capital Partners.
KEY ACCOUNTABILITIES
Requirements